{"entity":{"id":"nct07427394","kind":"trial","name":"Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer","aka":[],"tldr":"A phase 2 trial of Camizestrant and Atirmociclib in advanced solid tumours, run by AstraZeneca, now recruiting.","summary":"Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer is a phase 2 interventional study registered as NCT07427394 by AstraZeneca, with 24 participants planned, started 2026-05-06 and due to reach its primary completion in 2027-12-28. Interventions recorded: Camizestrant and Atirmociclib.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07427394","url":"https://clinicaltrials.gov/study/NCT07427394"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["camizestrant","atirmociclib"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07427394","phase":"2","setting":"A Phase IIa, Open-label Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of Camizestrant in Combination With Atirmociclib in Participants With ER-positive, HER2-negative Advanced Breast Cancer (SERENA-1b)","sponsor":"AstraZeneca","enrolled":24,"outcomes":[]},"route":"/trials/nct07427394/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"atirmociclib","kind":"drug","name":"Atirmociclib","route":"/drugs/atirmociclib/"},{"id":"camizestrant","kind":"drug","name":"Camizestrant","route":"/drugs/camizestrant/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}